
Dermik Laboratories, the U.S. dermatology arm of the Aventis pharmaceutical company, on Monday applied with the Food and Drug Administration for expedited premarket review of its lipoatrophy treatment Sculptra, currently available in Europe, South America, and Australia as New-Fill. The treatment is an injectable synthetic material that can help fill spaces left by the loss of fat under the skin, particularly in the face. New-Fill has been used by an estimated 100,000 people in 30 countries for the treatment of a range of facial problems, including wrinkles, folds, and sunken cheeks.
"Facial lipoatrophy is a condition that results in loss of fat in the cheeks, temples, and eye sockets," says Sharon Levy, senior director of scientific and medical affairs for Dermik Laboratories. "The sunken cheeks, hollow eyes, indentations, and wrinkling may make a person appear exhausted and unhealthy. Lipoatrophy can result from antiretroviral therapy in people with HIV and can have a devastating effect on self-image and confidence. The effects can be so severe that patients may even jeopardize their health by discontinuing their antiretroviral treatment."
The objective of the studies submitted to the FDA was to determine whether Sculptra safely and effectively produced significant improvements in appearance and in restoration of lost facial volume in people with HIV. Researchers also evaluated the quality of life as well as anxiety and depression scores of study participants. The data from these studies show that Sculptra is well-tolerated, with adverse effects generally limited to reactions at the site of the injection, company officials report.
Sculptra, a poly-L-lactic acid (PLLA), is synthetically derived from natural components and is a biocompatible substance that degrades to lactic acid, a substance naturally produced in the muscles of the body. PLLA has been used in surgical products for more than 20 years as a component of dissolvable sutures and is used in several sustained-release injectable medications.
Lipoatrophy, part of an overall condition called lipodystrophy, is a common problem for HIV-positive people taking antiretroviral drugs, particularly protease inhibitors. It is most often marked by subdermal fat loss in the face, arms, buttocks, and legs. Fat deposits also can form on the back and shoulders and in the stomach area as part of lipodystrophy. Elevated cholesterol and triglyceride levels are other common lipodystrophy symptoms.
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
Comments that do not concern specific articles in The Advocate or on Advocate.com will not be posted or published. See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.